Related Experiment Video
Updated: Aug 30, 2026
A Rhodopsin Transport Assay by High-Content Imaging Analysis
Published on: January 16, 2019
The nature of dominant mutations of rhodopsin and implications for gene therapy
John H Wilson1, Theodore G Wensel
1Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA. jwilson@bcm.tmc.edu
Abstract:
Mutations in the rhodopsin gene are the most common cause of retinitis pigmentosa (RP) among human patients. The nature of the rhodopsin mutations has critical implications for the design of strategies for gene therapy. Nearly all rhodopsin mutations are dominant. Although dominance does not arise because of haploinsufficiency, it is unclear whether it is caused by gain-of-function or dominant-negative mutations. Current strategies for gene therapy have been devised to deal with toxic, gain-of-function mutations. However, analysis of results of transgenic and targeted expression of various rhodopsin genes in mice suggests that dominance may arise as a result of dominant-negative mutations. This has important consequences for gene therapy. The effects of dominant-negative mutations can be alleviated, in principle, by supplementation with additional wild-type rhodopsin. If added wild-type rhodopsin could slow retinal degeneration in human patients, as it does in mice, it would represent a valuable new strategy for gene therapy of RP caused by dominant rhodopsin mutations.
Insights
Mutations in the rhodopsin gene cause retinitis pigmentosa (RP). Dominant-negative mutations, rather than gain-of-function, may underlie RP, suggesting wild-type rhodopsin supplementation as a gene therapy strategy.
Area of Science:
- Genetics
- Ophthalmology
- Molecular Biology
Background:
- Mutations in the rhodopsin gene are the primary cause of retinitis pigmentosa (RP) in humans.
- Understanding the nature of these rhodopsin mutations is crucial for developing effective gene therapies.
Purpose of the Study:
- To investigate whether dominant rhodopsin mutations causing RP are gain-of-function or dominant-negative.
- To explore the implications of mutation type for gene therapy strategies.
Main Methods:
- Analysis of transgenic and targeted expression of various rhodopsin genes in mouse models.
- Comparative analysis of mutation effects and potential therapeutic interventions.
Main Results:
- Evidence suggests that dominance in rhodopsin mutations may stem from dominant-negative effects, not solely gain-of-function.
- Transgenic mouse models indicate that wild-type rhodopsin can mitigate retinal degeneration.
Conclusions:
- Dominant-negative rhodopsin mutations are a significant factor in RP.
- Supplementation with wild-type rhodopsin presents a promising new gene therapy approach for RP patients with dominant rhodopsin mutations.
Related Concept Videos
01:11Channel Rhodopsins
Rhodopsins belong to the family of cell surface proteins called G-protein coupled receptors,...
01:22Photoreceptors and Visual Pathways
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:25Genetic Lingo
01:22Gene Therapy
01:09Epistasis Analysis